| GTO ID | GTC2083 |
| Trial ID | NCT03897881 |
| Disease | Melanoma |
| Therapy | mRNA vaccine |
| Treatment | mRNA-4157 |
| Co-treatment | Pembrolizumab |
| Phase | Phase2 |
| Recruitment status | Recruiting |
| Title | A Phase 2 Randomized Study of Adjuvant Immunotherapy With the Personalized Cancer Vaccine mRNA-4157 and Pembrolizumab Versus Pembrolizumab Alone After Complete Resection of High-Risk Melanoma (KEYNOTE- 942) |
| Year | 2019 |
| Country | United States|Australia |
| Company sponsor | ModernaTX, Inc. |
| Other ID(s) | mRNA-4157-P201 |
| Vector information | |||
|
|||
| Cohort1: mRNA-4157_Pembrolizumab | |||||||||||
|
|||||||||||
| Cohort2: Pembrolizumab | |||||||||||
|
|||||||||||